Amgen Seeks to Expand Use of Drug
- Share via
Amgen Inc. has asked the Food and Drug Administration to approve its Enbrel drug for patients with an inflammatory spinal disorder.
Enbrel has been sold since 1998 as a treatment for rheumatoid arthritis, an inflammation of the joints, and last year won approval for psoriatic arthritis.
Approval of Enbrel for ankylosing spondylitis could help the world’s largest biotechnology company expand its market for the drug. Amgen released study results last week suggesting that the medicine works against the chronic skin disorder psoriasis.
Amgen shares climbed $1.63 to $52.50 on Nasdaq.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
